Table 3 Cox Regression Analysis Examining Proteins relation to Incident Diabetes.

From: Using a Targeted Proteomics Chip to Explore Pathophysiological Pathways for Incident Diabetes– The Malmö Preventive Project

 

HR (95% CI)

p-value

HR (95% CI)

p-value

HR (95% CI)

p-value

Model 1

Model 2

Model 3

PON 3

0.65 (0.56–0.75)

3.3 × 10−9

0.79 (0.67–0.93)

0.005

0.81 (0.69–0.96)

0.014

FABP4

1.74 (1.44–2.10)

9.3 × 10−9

1.46 (1.16–1.84)

0.001

1.48 (1.17–1.87)

0.001

PAI

1.70 (1.41–2–05)

4.0 × 10−8

1.50 (1.21–1.84)

<0.0001

1.40 (1.14–1.72)

0.001

IGFBP-2

0.66 (0.56–0.77)

2.9 × 10−7

0.82 (0.68–0.99)

0.039

0.89 (0.74–1.08)

0.24

CD163

1.50 (1.26–1.77)

3.0 × 10−6

1.34 (1.11–1.60)

0.002

1.22 (1.02–1.46)

0.029

CTSD

1.33 (1.13–1.56)

5.2 × 10−4

1.20 (1.00–1.43)

0.050

1.08 (0.91–1.29)

0.39

Gal-4

1.37 (1.15–1.64)

5.4 × 10−4

1.30 (1.08–1.56)

0.005

1.27 (1.07–1.52)

0.008

  1. Cox regressions for incident diabetes (146 cases vs. 880 controls in the MPP) adjusted for age and sex (Model 1) and age, sex, BMI, HTN, lnTG, lnHDL lncystatin C and physical activity (Model 2) and age, sex, BMI, HTN, lnTG, lnHDL, lncystatin C, physical activity and lnglucose (Model 3). PON 3; Paraoxonase,,FABP4; fatty acid binding protein 4, PAI; Plasminogen activator inhibitor 1, IGFBP-2; Insulin-like growth factor-binding protein 2, CD163; scavenger receptor cysteine rich type 1 protein M130, CTSD; Cathepsin D, Gal-4; Galectin-4.
Back to article page